Eiger Biopharmaceuticals Inc. and AnGes Inc. announced that the companies entered into an agreement for the regulatory approval, marketing, and distribution of Zokinvy® (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS or progeria) and processing-deficient progeroid laminopathies (PL) in Japan. Under the terms of the agreement, AnGes is responsible for obtaining and maintaining regulatory approval for Zokinvy in Japan and will be the exclusive partner for distribution and commercialization. Eiger will receive upfront and milestone payments up to $1.5 million as well as earn revenue from the sale of Zokinvy to AnGes.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.67 USD | -12.17% | +11.72% | -60.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.36% | 3.95M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- EIGR Stock
- News Eiger BioPharmaceuticals, Inc.
- Eiger Biopharmaceuticals Inc. and AnGes Inc. Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® in Japan